<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Breast Cancer Prevention | Archangel Michael Health</title>

  <!-- Shared stylesheet (template-consistent) -->
  <link rel="stylesheet" href="https://docbraymd.github.io/amh/style_v2.css" />

  <!-- html2pdf for one-click PDF download -->
  <script defer src="https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.10.1/html2pdf.bundle.min.js"></script>
</head>

<body>
  <div class="amh-page main-container" id="pdf-root" role="document">
    <header class="amh-header">
      <div class="amh-header-inner amh-header-centered">
        <div class="amh-logo-wrap">
          <img class="amh-logo" src="https://docbraymd.github.io/amh/AMHLogo.png" alt="Archangel Michael Health logo" />
        </div>

        <div class="amh-practice doctor-tag">Archangel Michael Health</div>

        <h1 class="amh-title" id="page-title">Breast Cancer Prevention</h1>
        <h2 class="amh-tagline">Patient Guide: Lifestyle, Integrative &amp; Conventional Risk Reduction</h2>
        <div class="byline">by Christopher L. Bray MD PhD</div>

        <div class="action-bar amh-actions no-print" aria-label="Actions">
          <button class="amh-btn amh-btn-secondary" type="button" onclick="window.print()">
            Print / Save as PDF
          </button>
          <button class="amh-btn amh-btn-primary" id="downloadPdfBtn" type="button">
            Download PDF
          </button>
        </div>
      </div>
    </header>

    <div class="amh-content content-body">
      <p>
        Breast cancer risk is not a single “yes/no” property. It is a probability shaped by genetics, breast tissue biology,
        hormones, metabolic health, inflammation, lifestyle exposures, and (importantly) how well screening can actually see through your breast tissue.
        This guide is designed for sophisticated patients who want a rigorous, practical plan: foundations first, then targeted risk reduction,
        and escalation (enhanced imaging and/or medications) only when the risk/benefit profile makes sense.
        This is a prevention and early-detection guide (not a diagnosis page). References are provided at the end.
      </p>

      <div class="toc no-print" aria-label="On this page">
        <h2>On this page</h2>
        <ul class="amh-list">
          <li><a href="#overview">Overview and key points</a></li>
          <li><a href="#symptoms">Symptoms and red flags</a></li>
          <li><a href="#diagnosis">Diagnosis and what to test</a></li>
          <li><a href="#drivers">Root causes and contributing factors</a></li>
          <li><a href="#plan">Step-by-step improvement plan</a></li>
          <li><a href="#treatments">Conventional care: screening and high-risk prevention</a></li>
          <li><a href="#integrative">Integrative options: foods, spices, supplements</a></li>
          <li><a href="#costs">Cost considerations</a></li>
          <li><a href="#faq">FAQ</a></li>
          <li><a href="#references">References</a></li>
        </ul>
      </div>

      <h3 id="overview">Overview and key points</h3>

      <div class="success-box">
        <strong>High-yield summary:</strong>
        The highest “return on effort” for primary prevention is a staged approach:
        (1) reduce alcohol and avoid tobacco; (2) maintain a healthy waistline and improve insulin sensitivity;
        (3) exercise consistently; (4) eat a Mediterranean / plant-forward dietary pattern rich in fiber and phytonutrients;
        (5) use hormones thoughtfully (birth control and HRT are not “free” from a risk standpoint);
        (6) know your breast density and perform a formal risk calculation; and (7) reserve medications (tamoxifen, raloxifene, aromatase inhibitors)
        and enhanced imaging (MRI) for patients whose calculated risk justifies the tradeoffs.
      </div>

      <div class="clinical-note">
        <strong>Clinical note: what “prevention” really means.</strong>
        Prevention has two domains: (1) <em>primary prevention</em> (reduce the chance a cancer forms),
        and (2) <em>secondary prevention</em> (detect cancer earlier when it is more treatable).
        Screening saves lives, but it can also cause harm via false alarms, unnecessary biopsies, anxiety,
        radiation exposure, and “overdiagnosis” (finding a cancer that would not have harmed you in your lifetime).
        The goal is individualized prevention: enough screening and intervention to reduce meaningful risk, but not so much that you incur avoidable harm.
      </div>

      <h4>Key concepts to understand</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Breast density is a “double jeopardy” factor:</strong> it increases biological risk and reduces the ability of mammography to detect tumors.</li>
        <li><strong>Risk calculators matter:</strong> the same person may be “average risk” on one model and “high risk” on another, changing whether MRI or medications are appropriate.</li>
        <li><strong>Hormones are powerful:</strong> lifetime estrogen/progesterone exposure influences risk. The tradeoffs around oral contraceptives and menopausal hormone therapy deserve deliberate decision-making.</li>
        <li><strong>Metabolic health matters:</strong> after menopause, excess adipose tissue becomes a major estrogen source; insulin resistance and chronic inflammation amplify proliferative signaling.</li>
        <li><strong>Supplements are secondary:</strong> the most reliable benefits come from lifestyle patterns; supplements may be adjuncts, not substitutes.</li>
      </ul>

      <hr />

      <h3 id="symptoms">Symptoms and red flags</h3>
      <p>
        Most early breast cancers cause no symptoms. That is why risk-appropriate screening and follow-up of abnormal findings matters.
        Still, you should know what warrants prompt evaluation.
      </p>

      <h4>Possible breast cancer symptoms</h4>
      <ul class="amh-list symptom-list">
        <li>New lump or thickening in the breast or underarm (especially if firm, irregular, or fixed).</li>
        <li>Change in breast size or shape that is new and persistent.</li>
        <li>Skin changes: dimpling, puckering, new redness, or “peau d’orange” (orange-peel texture).</li>
        <li>Nipple changes: new inversion, scaling, ulceration, or persistent crusting.</li>
        <li>Spontaneous nipple discharge, especially if bloody or from one duct.</li>
        <li>Persistent, focal breast pain (pain alone is usually not cancer, but persistent focal pain deserves evaluation).</li>
      </ul>

      <div class="alert-box">
        <strong>Red flags (seek prompt clinical evaluation):</strong>
        rapidly enlarging breast swelling or redness (possible inflammatory breast cancer or infection),
        a new hard mass with skin tethering,
        bloody nipple discharge,
        or a new lump in the armpit that persists.
        If you have fever with breast redness and are breastfeeding, mastitis is common—but if symptoms do not improve quickly with appropriate treatment, reassessment is important.
      </div>

      <hr />

      <h3 id="diagnosis">Diagnosis and what to test</h3>
      <p>
        For prevention, “diagnosis” means two things: (1) quantify risk accurately, and (2) match screening intensity to risk (and breast density).
        The highest-value tests are those that change management.
      </p>

      <h4>1) Determine your baseline risk category</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Average risk:</strong> no strong family history, no high-risk gene mutation known, no prior high-risk breast lesion, no chest radiation at young age.</li>
        <li><strong>Increased risk:</strong> family history (especially young diagnoses), certain benign lesions (atypical hyperplasia, LCIS), elevated risk scores on calculators, dense breasts plus other risk factors.</li>
        <li><strong>High risk:</strong> known pathogenic mutation (e.g., BRCA1/2, TP53, PALB2), strong hereditary pattern, prior chest radiation (especially before age 30), or lifetime risk ≥20% on validated models.</li>
      </ul>

      <h4>2) Use validated breast cancer risk calculators (and understand their limitations)</h4>
      <div class="clinical-note">
        <strong>Why calculators matter:</strong> Chemoprevention and MRI screening are generally guided by calculated thresholds.
        Different tools weigh different variables, so a single “risk score” should be treated as decision-support—not destiny.
      </div>

      <ul class="amh-list symptom-list">
        <li><strong>Gail Model / BCRAT:</strong> practical for primary care and for determining medication eligibility based on 5-year risk. Limitations: less complete family history modeling and typically does not incorporate breast density.</li>
        <li><strong>Tyrer-Cuzick / IBIS:</strong> more comprehensive (often includes second-degree relatives, BMI, hormones, and breast density). Commonly used to determine eligibility for MRI screening based on lifetime risk.</li>
        <li><strong>BRCAPRO (carrier probability):</strong> estimates probability of carrying BRCA mutations from detailed pedigree. Useful for deciding on referral to genetic counseling and testing.</li>
        <li><strong>Claus model (family history):</strong> older, family-history based tool; sometimes used but often replaced by more comprehensive models.</li>
      </ul>

      <h4>Practical risk thresholds that commonly change management</h4>
      <ul class="amh-list symptom-list">
        <li><strong>5-year Gail risk ≥1.67%:</strong> traditional threshold to discuss risk-reducing medication; some guidance uses ≥3% as the point where benefits more clearly outweigh harms.</li>
        <li><strong>Lifetime risk ≥20%:</strong> typically qualifies for annual breast MRI in addition to mammography.</li>
        <li><strong>BRCAPRO carrier probability ≥10% or hereditary red flags:</strong> usually warrants genetic counseling/testing consideration.</li>
      </ul>

      <h4>3) Know your breast density</h4>
      <p>
        Breast density is determined by mammography and reported as one of four categories (from mostly fatty to extremely dense).
        Dense tissue can “hide” tumors on mammogram because both dense tissue and tumors appear white.
      </p>
      <ul class="amh-list symptom-list">
        <li><strong>Risk impact:</strong> extremely dense breasts can carry substantially higher risk compared with fatty breasts.</li>
        <li><strong>Detection impact:</strong> the sensitivity of mammography is much higher in fatty breasts and substantially lower in extremely dense breasts.</li>
        <li><strong>Action:</strong> if you have dense breasts, you should discuss whether you need supplemental screening (tomosynthesis, ultrasound, contrast-enhanced mammography, or MRI), guided by your total risk profile.</li>
      </ul>

      <h4>4) Testing that may be reasonable in a prevention-focused clinic</h4>
      <p>
        These tests are not “breast cancer tests,” but they can identify modifiable physiologic drivers that influence risk (especially metabolic and inflammatory risk).
        Testing should be individualized—best used when results will drive a concrete plan.
      </p>
      <ul class="amh-list symptom-list">
        <li><strong>Metabolic risk:</strong> fasting glucose, A1c, fasting insulin (or insulin resistance markers), lipid panel, blood pressure, waist circumference.</li>
        <li><strong>Inflammation (selective):</strong> hs-CRP may help contextualize inflammatory risk and lifestyle priorities.</li>
        <li><strong>Vitamin D:</strong> reasonable to check if low sun exposure, osteoporosis risk, autoimmune disease, or if supplementation is being considered.</li>
        <li><strong>Genetics:</strong> referral/testing when family history patterns or risk model outputs suggest hereditary risk.</li>
      </ul>

      <hr />

      <h3 id="drivers">Root causes and contributing factors</h3>
      <p>
        You cannot change every variable. Some risks are “fixed” (sex, age, genetics), but many are modifiable.
        The prevention strategy is to identify the few levers that meaningfully change your probability.
      </p>

      <h4>Non-modifiable or minimally modifiable factors</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Age:</strong> risk rises with age, especially after midlife.</li>
        <li><strong>Genetics:</strong> high-penetrance mutations (e.g., BRCA1/2, TP53, PALB2) materially change strategy (MRI, medications, sometimes surgery).</li>
        <li><strong>Personal breast history:</strong> atypical hyperplasia, LCIS, or prior breast cancer increases future risk.</li>
        <li><strong>Chest radiation at a young age:</strong> substantially increases lifetime risk.</li>
      </ul>

      <h4>High-impact modifiable factors (best ROI)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Alcohol intake:</strong> the most consistently supported dietary risk factor for breast cancer.</li>
        <li><strong>Tobacco exposure:</strong> active smoking and prolonged exposure increases risk and worsens overall cancer and cardiovascular outcomes.</li>
        <li><strong>Body fat distribution and insulin resistance:</strong> after menopause, adipose tissue becomes a significant estrogen source; insulin/IGF signaling amplifies proliferation.</li>
        <li><strong>Physical inactivity:</strong> exercise reduces risk through weight-dependent and weight-independent mechanisms (hormonal, immune, inflammatory, metabolic).</li>
        <li><strong>Dietary pattern:</strong> fiber intake, plant diversity, and overall dietary quality influence estrogen metabolism, inflammation, and insulin sensitivity.</li>
        <li><strong>Hormone exposures:</strong> oral contraceptives and menopausal hormone therapy can alter risk; decisions should be individualized.</li>
      </ul>

      <h4>Additional contributing factors worth addressing</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Sleep/circadian disruption:</strong> irregular sleep and night shift work may contribute via melatonin and metabolic pathways.</li>
        <li><strong>Reproductive history:</strong> earlier menarche, later first birth, and not breastfeeding can increase risk modestly via lifetime hormone exposure patterns.</li>
        <li><strong>Environmental exposures:</strong> endocrine-disrupting chemicals (EDCs) plausibly matter; the highest-yield approach is to reduce high-frequency exposures (food packaging, fragrances, certain plastics, solvents), without turning life into a fear project.</li>
      </ul>

      <hr />

      <h3 id="plan">Step-by-step improvement plan</h3>
      <div class="success-box">
        <strong>Practical plan:</strong> Most patients do best with a staged strategy:
        (1) quantify risk + clarify screening; (2) implement the “big levers” (alcohol, weight/insulin resistance, exercise, dietary pattern);
        (3) address hormones and breastfeeding history where relevant; (4) consider targeted integrative adjuncts; and (5) if risk thresholds are met,
        discuss MRI and/or medications (tamoxifen, raloxifene, aromatase inhibitors).
      </div>

      <h4>Step 0: Clarify your “starting point” (one-time setup)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Get your breast density from your mammogram report.</strong></li>
        <li><strong>Run a formal risk assessment:</strong> ideally Tyrer-Cuzick/IBIS (especially if dense breasts or extended family history) and consider Gail/BCRAT for 5-year risk framing.</li>
        <li><strong>Review family history:</strong> breast, ovarian, pancreatic, prostate cancers; ages at diagnosis; maternal and paternal sides.</li>
        <li><strong>Decide on a screening strategy:</strong> based on age, density, and risk model results (see Conventional Care).</li>
      </ul>

      <h4>Step 1 (Weeks 1–4): Foundations that move risk the most</h4>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Alcohol strategy</div>
          <div class="rx-type">FOUNDATION</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Why it matters</div>
          <div>
            Alcohol is the dietary exposure with the strongest evidence for increasing breast cancer risk.
            Mechanisms include higher estrogen levels, oxidative stress, acetaldehyde toxicity, and impaired folate metabolism.
          </div>

          <div class="rx-label">Practical target</div>
          <div>
            Best prevention target is <strong>zero</strong>. If you choose to drink, aim for the lowest frequency and dose possible.
            If you currently drink most days, your first win is reducing to occasional use.
          </div>

          <div class="rx-label">High-yield steps</div>
          <div>
            Replace “default alcohol” with an alternate ritual (sparkling water + citrus, tea, or a non-alcoholic botanical beverage);
            avoid drinking on an empty stomach; avoid “stress drinking” by building alternative stress outlets.
          </div>

          <div class="rx-label">Safety / cautions</div>
          <div>
            Alcohol also increases hypertension, atrial fibrillation risk, sleep disruption, depression/anxiety risk, and multiple other cancers.
            If you use alcohol to manage anxiety or sleep, treat the underlying issue—alcohol is a net negative for both.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often cost-saving: less alcohol generally reduces spending and improves health ROI.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Exercise prescription (risk reduction + metabolic health)</div>
          <div class="rx-type">FOUNDATION</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Why it matters</div>
          <div>
            Exercise improves insulin sensitivity, lowers chronic inflammation, improves immune surveillance, reduces visceral fat,
            and can lower postmenopausal estrogen exposure indirectly through reduced adiposity.
          </div>

          <div class="rx-label">Practical target</div>
          <div>
            <strong>150–300 minutes/week</strong> of moderate aerobic activity plus <strong>2</strong> resistance training sessions/week.
            If you do not exercise now, begin with 10–20 minutes/day and build.
          </div>

          <div class="rx-label">High-yield structure</div>
          <div>
            Most patients do well with: (1) a daily baseline (walk after meals), (2) two “longer sessions” weekly,
            and (3) resistance training focused on major muscle groups (squats/hinges/push/pull/carry).
          </div>

          <div class="rx-label">Safety / cautions</div>
          <div>
            If you have known cardiovascular disease, severe orthopedic limitations, or unexplained exertional symptoms, discuss a safe ramp-up plan.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Low-cost options: walking, cycling, home resistance bands/dumbbells. Gym membership is optional, not required.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Weight and insulin-resistance strategy (especially important after menopause)</div>
          <div class="rx-type">FOUNDATION</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Why it matters</div>
          <div>
            After menopause, adipose tissue becomes a major source of estrogen via aromatase activity.
            Insulin resistance increases IGF signaling and inflammatory pathways that favor proliferation.
          </div>

          <div class="rx-label">Practical target</div>
          <div>
            Focus less on scale weight and more on <strong>waist circumference</strong>, <strong>body composition</strong>, and <strong>metabolic markers</strong>.
            Aim for steady, sustainable improvement rather than rapid dieting cycles.
          </div>

          <div class="rx-label">High-yield steps</div>
          <div>
            Protein-forward breakfasts, high fiber (beans, lentils, vegetables), limit ultra-processed foods,
            build daily movement, and prioritize sleep. Consider time-restricted eating if appropriate (see below).
          </div>

          <div class="rx-label">Safety / cautions</div>
          <div>
            If you have a history of eating disorder, pregnancy, or medical conditions requiring tight glucose control,
            fasting strategies should be clinician-guided.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often cost-neutral if you substitute legumes/whole foods for packaged foods and alcohol.
          </div>
        </div>
      </div>

      <h4>Step 2 (Weeks 4–12): Dietary pattern and hormone strategy</h4>

      <div class="clinical-note">
        <strong>Diet “pattern” beats individual superfoods.</strong>
        For prevention, the strongest nutrition evidence generally supports a Mediterranean / plant-forward pattern:
        high vegetable and legume intake, fiber, healthy fats (olive oil, nuts), limited ultra-processed foods,
        and minimal alcohol. Specific foods and spices can be layered in as targeted adjuncts (see Integrative Options).
      </div>

      <h4>Dietary pattern targets (practical and measurable)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Vegetables:</strong> 5+ servings/day; aim for color diversity. Include cruciferous vegetables several times/week.</li>
        <li><strong>Fiber:</strong> build toward 25–40 g/day (beans/lentils, vegetables, chia/flax, whole grains as tolerated).</li>
        <li><strong>Protein:</strong> prioritize legumes, fish, and minimally processed protein sources; limit processed meats.</li>
        <li><strong>Fats:</strong> olive oil, nuts, seeds; avoid routinely deep-fried foods and trans fats.</li>
        <li><strong>Ultra-processed foods:</strong> reduce frequency and portion size—these often drive insulin resistance and weight gain.</li>
      </ul>

      <h4>Hormones: birth control and menopausal hormone therapy (HRT)</h4>
      <p>
        Hormones are among the most nuanced parts of prevention because they are not “good” or “bad” universally—benefit depends on why they are used,
        at what dose, and in whom. The core principle is to use the lowest effective dose for the shortest necessary time, and to consider non-hormonal alternatives when appropriate.
      </p>

      <ul class="amh-list symptom-list">
        <li><strong>Oral contraceptives:</strong> current or recent use is associated with a modest increase in breast cancer risk; risk trends back toward baseline after stopping over time. This must be balanced against benefits (pregnancy prevention, cycle control, ovarian/endometrial cancer risk reduction, symptom control).</li>
        <li><strong>Menopausal hormone therapy:</strong> combined estrogen-progestin therapy increases breast cancer risk more than estrogen-only therapy. Timing, formulation, dose, route (oral vs transdermal), and duration matter. The goal is individualized symptom relief while minimizing long-term exposure.</li>
        <li><strong>High-risk patients:</strong> if you have elevated calculated risk, dense breasts, prior high-risk lesions, or strong family history, hormone decisions should be more conservative and collaborative.</li>
      </ul>

      <h4>Breastfeeding</h4>
      <p>
        If you have children and breastfeeding is feasible and desired, longer cumulative breastfeeding duration is associated with meaningful protective effect.
        Breastfeeding is not “required” for health, but it is a genuine risk-reduction lever when it aligns with your life circumstances.
      </p>

      <h4>Fasting and time-restricted eating (TRE)</h4>
      <p>
        The best evidence for fasting in breast cancer is stronger for <em>metabolic health</em> and (in some studies) outcomes in survivors rather than direct proof of primary prevention.
        Nevertheless, because insulin resistance and visceral adiposity contribute to risk, TRE can be a practical tool for some patients.
      </p>

      <ul class="amh-list symptom-list">
        <li><strong>Low-risk, practical approach:</strong> aim for a consistent overnight fasting window (for example, a 12–13 hour break between dinner and breakfast).</li>
        <li><strong>Most important rule:</strong> fasting should not become a stressor or lead to binge-restrict cycles.</li>
        <li><strong>Who should be cautious:</strong> pregnancy, breastfeeding (individualized), eating disorder history, underweight, frailty, and certain diabetes medication regimens.</li>
      </ul>

      <h4>Sauna</h4>
      <p>
        Sauna use can improve relaxation and may improve cardiovascular and metabolic markers in some populations, but it is not proven as a breast cancer prevention strategy.
        Use sauna as a wellness adjunct—not as a replacement for the high-ROI levers (alcohol, exercise, weight/metabolic health).
      </p>

      <hr />

      <h3 id="treatments">Conventional care: screening and high-risk prevention</h3>
      <p>
        Conventional prevention is fundamentally about <strong>risk-stratified screening</strong> (detect earlier) and,
        for higher-risk individuals, <strong>risk-reducing medication</strong> and occasionally <strong>risk-reducing surgery</strong>.
        The correct strategy depends on your age, breast density, personal risk factors, and risk model outputs.
      </p>

      <h4>Screening: what standard-of-care is trying to do</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Mammography</strong> reduces breast cancer mortality in screened populations, especially as age increases.</li>
        <li><strong>Harms exist:</strong> false positives, unnecessary biopsies, anxiety, and overdiagnosis (detecting a cancer that would not have harmed you).</li>
        <li><strong>Breast density changes the equation:</strong> dense tissue both increases risk and reduces mammography sensitivity, sometimes justifying supplemental screening.</li>
      </ul>

      <div class="clinical-note">
        <strong>How to interpret “benefit vs harm” numbers.</strong>
        Many screening statistics are reported per 1,000 women screened over a time horizon (often 10 years).
        Numbers vary across studies and models, so treat them as “order-of-magnitude” decision aids—not precise predictions for an individual.
      </div>

      <h4>Screening tradeoffs by age (typical 10-year framing)</h4>
      <ul class="amh-list symptom-list">
        <li>
          <strong>Women 40–49 (biennial screening):</strong> modest mortality benefit for the group, with a relatively high burden of false positives and biopsies.
          Over a decade, many women experience at least one false alarm; a smaller number undergo benign biopsies; and a small number experience overdiagnosis.
        </li>
        <li>
          <strong>Women 50–74:</strong> mortality benefit is clearer at the population level, and the number needed to screen to prevent one death improves with age.
          Overdiagnosis remains a real concern, especially as age advances.
        </li>
        <li>
          <strong>Women 70+:</strong> the balance becomes increasingly individualized (life expectancy, comorbidities, functional status, and personal values).
          Overdiagnosis risk increases as competing mortality increases.
        </li>
      </ul>

      <div class="alert-box">
        <strong>Important:</strong> If you have a strong family history, a high-risk lesion (atypia/LCIS), a high-risk genetic mutation,
        or prior chest radiation, you are not an “average risk screening” patient. Your screening and prevention plan should be escalated appropriately.
      </div>

      <h4>Breast density: how it changes screening and why it matters</h4>
      <p>
        Dense breasts reduce mammography sensitivity and increase the chance of interval cancers (cancers that appear between screenings).
        If you have dense breasts, do not stop at “normal mammogram”—discuss whether supplemental screening is appropriate given your total risk.
      </p>

      <h4>Supplemental screening options (most common)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>3D Tomosynthesis (3D mammogram):</strong> improves detection and generally reduces false positive callbacks compared with 2D alone. Often a good default if available.</li>
        <li><strong>Ultrasound:</strong> can detect additional cancers in dense breasts but increases false positives and benign biopsies.</li>
        <li><strong>Breast MRI:</strong> highest sensitivity; typically reserved for high-risk women or selected dense-breast patients with additional risk factors due to cost, access, and higher false positive rate.</li>
        <li><strong>Abbreviated MRI (AB-MRI):</strong> shorter protocol in some centers; may improve accessibility while maintaining strong sensitivity, though availability varies.</li>
        <li><strong>Contrast-enhanced mammography (CEM):</strong> emerging/expanding tool in some centers; may be considered where available.</li>
      </ul>

      <h4>Enhanced prevention for increased-risk and high-risk individuals</h4>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Breast MRI screening (for high-risk patients)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            Contrast-enhanced MRI imaging with the highest sensitivity for breast cancer detection. Usually used annually in high-risk patients,
            in addition to (not instead of) mammography.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            MRI detects vascular and tissue characteristics of cancer. It is less affected by breast density than mammography.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Often used when lifetime risk is ≥20%, when high-risk genetics are present, when there is prior chest radiation at a young age,
            or when there are high-risk lesions and the overall risk profile supports escalation.
          </div>

          <div class="rx-label">Side effects / downsides</div>
          <div>
            Higher false positive callback and biopsy rates; requires IV contrast (gadolinium) and is not appropriate for some patients with severe kidney disease.
            Claustrophobia and access/cost are common barriers.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often covered for high-risk indications; out-of-pocket costs can be substantial without coverage. AB-MRI may be less expensive where offered.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Risk-reducing medications (chemoprevention)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            Medications that reduce the probability of developing hormone receptor–positive breast cancer in women at elevated risk.
            These are prevention medications, not chemotherapy.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            Most breast cancers are estrogen receptor positive. These drugs reduce estrogen signaling (SERMs like tamoxifen/raloxifene)
            or reduce estrogen synthesis (aromatase inhibitors like anastrozole/exemestane).
          </div>

          <div class="rx-label">Who benefits most</div>
          <div>
            Women with elevated 5-year risk or high-risk lesions (atypical hyperplasia, LCIS), and selected high-risk women based on risk model outputs.
          </div>

          <div class="rx-label">Downsides</div>
          <div>
            Side effects and rare serious harms exist. The key is ensuring your baseline risk is high enough that the absolute benefit outweighs these risks.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often inexpensive as generics, but total cost includes follow-up, management of side effects, and the burden of taking a daily medication for years.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Tamoxifen (SERM)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            A selective estrogen receptor modulator (SERM). It blocks estrogen signaling in breast tissue.
            Used for risk reduction in higher-risk premenopausal and postmenopausal women, and also used in treatment settings.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            Competes with estrogen at the receptor in breast tissue, reducing estrogen-driven proliferation.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Often a multi-year course (commonly 5 years) for prevention in appropriately selected higher-risk individuals.
            Selection is based on a formal risk assessment and shared decision-making.
          </div>

          <div class="rx-label">Side effects</div>
          <div>
            Hot flashes, mood changes, vaginal symptoms; rare but serious: venous thromboembolism, stroke risk in selected populations,
            and increased endometrial cancer risk (primarily in postmenopausal women).
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Generic is usually low-cost (often inexpensive monthly), but monitoring and side-effect management matter.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Raloxifene (SERM; postmenopausal)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            A SERM used in postmenopausal women for osteoporosis and for breast cancer risk reduction in selected higher-risk patients.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            Estrogen antagonist effects in breast tissue; estrogen agonist effects in bone (helpful for bone density).
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Prevention option for postmenopausal women when the risk profile supports benefit and when side-effect profile is acceptable.
          </div>

          <div class="rx-label">Side effects</div>
          <div>
            Hot flashes, leg cramps; rare serious: venous thromboembolism. Typically lower endometrial cancer risk compared with tamoxifen.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Generic often moderate-to-low monthly cost.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Aromatase inhibitors (anastrozole, exemestane; postmenopausal)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            Medications that reduce estrogen synthesis by inhibiting aromatase. Used for prevention in selected higher-risk postmenopausal women.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            Lowers systemic estrogen levels, reducing estrogen-driven proliferation in breast tissue.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Considered when baseline risk is sufficiently elevated (often based on risk calculators or high-risk lesions).
            Requires attention to bone health.
          </div>

          <div class="rx-label">Side effects</div>
          <div>
            Joint/muscle pains, hot flashes, decreased libido; long-term concern: bone loss and fracture risk.
            Bone density monitoring and bone-protective strategies are often needed.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often low-cost as generic, though bone monitoring and side-effect management add indirect costs.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Risk-reducing surgery (very high risk)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>
            Bilateral prophylactic mastectomy and/or risk-reducing salpingo-oophorectomy in carefully selected patients with very high hereditary risk.
          </div>

          <div class="rx-label">How it works</div>
          <div>
            Removes the highest-risk tissue (breast) and/or reduces ovarian estrogen production (oophorectomy), lowering risk substantially in mutation carriers.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Usually reserved for high-penetrance mutation carriers (e.g., BRCA1/2, TP53, PALB2) or exceptionally high lifetime risk with strong preference.
            Requires multidisciplinary counseling (genetics, surgery, oncology, and psychosocial support).
          </div>

          <div class="rx-label">Side effects / downsides</div>
          <div>
            Major surgery with permanent body changes; possible complications; potential impact on identity and sexual health.
            Oophorectomy causes surgical menopause and can have significant quality-of-life implications.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Often covered when medically indicated. Total cost includes surgery, reconstruction (if chosen), recovery time, and follow-up care.
          </div>
        </div>
      </div>

      <hr />

      <h3 id="integrative">Integrative options: foods, spices, supplements</h3>
      <p>
        Integrative prevention should be disciplined: prioritize interventions that are (1) safe, (2) plausible mechanistically,
        (3) consistent with population-level evidence, and (4) additive to (not replacing) the proven levers.
        In most cases, <strong>food-first</strong> delivers more benefit and fewer risks than high-dose supplements.
      </p>

      <div class="alert-box">
        <strong>Safety first:</strong> “Natural” does not automatically mean safe.
        Many supplements interact with anticoagulants, antiplatelet agents, seizure medications, thyroid medications, SSRIs/SNRIs,
        and hormone therapies. If you are pregnant, breastfeeding, have liver disease, or have a history of estrogen-sensitive cancer,
        supplement choices should be clinician-guided.
      </div>

      <h4>Food-first prevention stack (high ROI)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Cruciferous vegetables:</strong> broccoli, broccoli sprouts, Brussels sprouts, cabbage, kale, arugula (sulforaphane and related compounds support detoxification enzymes and may reduce carcinogen activation).</li>
        <li><strong>Allium family:</strong> garlic, onions, leeks (organosulfur compounds; antioxidant and detoxification support).</li>
        <li><strong>Flaxseed (ground):</strong> lignans may shift estrogen metabolism toward less proliferative pathways; easy to implement daily.</li>
        <li><strong>Soy foods (whole foods):</strong> tofu, tempeh, edamame, unsweetened soy milk (isoflavones; evidence generally supports safety of moderate intake and possible benefit, especially as whole foods).</li>
        <li><strong>Polyphenol-rich plants:</strong> berries, green tea, herbs/spices, colorful vegetables (antioxidant and anti-inflammatory signaling support).</li>
        <li><strong>Fiber and legumes:</strong> beans/lentils improve insulin sensitivity and support estrogen elimination via the gut.</li>
      </ul>

      <h4>Spices and culinary herbs (reasonable, low-risk adjuncts)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Turmeric + black pepper:</strong> curcumin is anti-inflammatory; black pepper (piperine) improves absorption.</li>
        <li><strong>Ginger:</strong> anti-inflammatory and supports metabolic health; easy food-based use.</li>
        <li><strong>Rosemary, oregano, thyme:</strong> polyphenols; easy daily culinary use.</li>
        <li><strong>Cinnamon:</strong> may modestly support glucose control in some individuals.</li>
      </ul>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Ground flaxseed</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>
            Rich source of lignans; gut metabolism produces enterolignans that may modulate estrogen metabolism toward less proliferative metabolites.
            Food-based intervention with favorable safety profile for most patients.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Common “food dose” is about <strong>2 tablespoons/day</strong> of <strong>ground</strong> flaxseed (whole seeds are often not digested).
            Mix into yogurt, oatmeal, smoothies, or sprinkle on salads.
          </div>

          <div class="rx-label">Safety</div>
          <div>
            Increase gradually if you are not used to fiber to avoid bloating; hydrate. If on anticoagulants, discuss with your clinician (food doses are typically fine, but context matters).
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Low monthly cost; usually one of the best ROI integrative options.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Cruciferous vegetables / sulforaphane strategy</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>
            Crucifers provide glucosinolates that convert to isothiocyanates (including sulforaphane) which support phase II detoxification enzymes
            and may reduce activation of certain carcinogens.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Food-first: include crucifers several times/week. Highest yield for sulforaphane often comes from broccoli sprouts.
            Practical approach: add sprouts to salads/sandwiches; lightly cook mature broccoli.
          </div>

          <div class="rx-label">Safety</div>
          <div>
            Generally safe as foods. If you have significant thyroid disease, crucifers are still usually safe as part of a varied diet,
            but avoid extreme “single food” approaches.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Low-to-moderate; sprouts can be purchased or grown at home.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Green tea (food-first) / EGCG (caution with extracts)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>
            Green tea provides polyphenols (including EGCG) with plausible anti-proliferative and anti-angiogenic mechanisms.
            Observational data suggest possible modest benefit.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Prefer brewed tea (e.g., 2–3 cups/day if tolerated). Matcha provides higher polyphenol exposure than steeped tea.
          </div>

          <div class="rx-label">Safety</div>
          <div>
            <strong>Avoid high-dose green tea extract capsules</strong> unless clinically justified and monitored—concentrated extracts have been associated with liver injury in some cases.
            If you have liver disease, prioritize brewed tea or avoid.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Low for brewed tea; supplements vary widely and are often unnecessary.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Curcumin (as food and, selectively, as supplement)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>
            Curcumin has anti-inflammatory signaling effects and plausible anti-proliferative mechanisms in experimental models.
            Human prevention evidence is evolving; best considered as an adjunct.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Food-based: cook with turmeric regularly (with black pepper and fat). If using a supplement, prefer enhanced-bioavailability formulations.
            Use should be individualized, not automatic.
          </div>

          <div class="rx-label">Safety</div>
          <div>
            Can worsen reflux in some; caution with anticoagulants/antiplatelets; caution if gallbladder disease. Avoid “mega-dosing” without oversight.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Food use is low-cost. Supplements typically moderate monthly cost depending on formulation.
          </div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Vitamin D (supportive, not a proven prevention pill)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>
            Low vitamin D is associated with multiple adverse outcomes; direct proof that supplementation prevents breast cancer is not strong.
            Still, maintaining a reasonable vitamin D level is often appropriate for bone and immune health.
          </div>

          <div class="rx-label">Typical use</div>
          <div>
            Test if clinically indicated. Supplementation dose should be individualized to your baseline level, sun exposure, and risk factors.
          </div>

          <div class="rx-label">Safety</div>
          <div>
            Excess dosing can cause hypercalcemia. Use lab-guided dosing if taking higher doses.
          </div>

          <div class="rx-label">Cost</div>
          <div>
            Usually inexpensive monthly.
          </div>
        </div>
      </div>

      <p>
        <strong>Bottom line:</strong> If you want the highest-confidence integrative prevention strategy, prioritize the food pattern:
        crucifers + alliums + fiber/legumes + flax + limited alcohol + consistent exercise. Supplements can be layered in selectively,
        but they should not distract from the big levers.
      </p>

      <hr />

      <h3 id="costs">Cost considerations</h3>
      <ul class="amh-list symptom-list">
        <li><strong>Highest ROI interventions are often low-cost:</strong> alcohol reduction, walking after meals, resistance training, legumes/vegetables, sleep discipline.</li>
        <li><strong>Screening costs vary:</strong> mammography is commonly covered; MRI and supplemental imaging costs vary widely by indication and insurance coverage.</li>
        <li><strong>Genetic counseling/testing:</strong> may be covered when criteria are met; out-of-pocket can vary based on pathway and lab.</li>
        <li><strong>Medications:</strong> most chemoprevention drugs are generic and often affordable, but side effects and monitoring (especially bone health for aromatase inhibitors) add indirect cost.</li>
        <li><strong>Supplements:</strong> avoid “stacking” many products. Choose a few high-signal, low-risk, food-first strategies; reserve supplements for clear rationale.</li>
      </ul>

      <hr />

      <h3 id="faq">FAQ</h3>

      <h4>Is there a “safe” amount of alcohol for breast cancer prevention?</h4>
      <p>
        From a strict prevention perspective, the lowest-risk choice is to avoid alcohol. If you drink, reducing frequency and dose meaningfully improves risk exposure.
        If you are trying to decide whether alcohol is “worth it,” remember alcohol affects far more than cancer risk (sleep, blood pressure, arrhythmias, mood, liver health).
      </p>

      <h4>Do dense breasts automatically mean I need MRI?</h4>
      <p>
        Not automatically. Dense breasts increase risk and reduce mammography sensitivity, but the correct next step depends on your total risk profile.
        Many patients do well with 3D tomosynthesis; others benefit from supplemental ultrasound or MRI based on calculated risk.
      </p>

      <h4>Should I take a “breast cancer prevention supplement stack”?</h4>
      <p>
        Usually no. Food-based patterns have the best safety and broad metabolic benefits. If supplements are used, choose a small number with clear rationale and safety,
        and do not use them as a substitute for alcohol reduction, exercise, and weight/metabolic health.
      </p>

      <h4>If I am high risk, should I get a prophylactic mastectomy?</h4>
      <p>
        That is a deeply personal decision. For very high-risk mutation carriers, surgery can offer the largest risk reduction, but it carries major physical and psychosocial tradeoffs.
        Many high-risk patients choose enhanced screening and/or medication instead. A multidisciplinary discussion is essential.
      </p>

      <h4>What is overdiagnosis, and why does it matter?</h4>
      <p>
        Overdiagnosis is finding a cancer through screening that would not have harmed you in your lifetime.
        The problem is that once discovered, it is typically treated—exposing a patient to surgery, radiation, and/or medications that did not improve longevity.
        Overdiagnosis risk increases with age and comorbidity; this is a major reason screening decisions after age 70 should be individualized.
      </p>

      <hr />

      <h3 id="references">References</h3>
      <ol class="ref-list">
        <li>U.S. Preventive Services Task Force (USPSTF). Breast Cancer: Screening. <a href="https://www.uspreventiveservicestaskforce.org/" target="_blank" rel="noopener">https://www.uspreventiveservicestaskforce.org/</a></li>
        <li>American Cancer Society (ACS). Breast Cancer Screening Guidelines. <a href="https://www.cancer.org/" target="_blank" rel="noopener">https://www.cancer.org/</a></li>
        <li>American College of Radiology (ACR). Breast Cancer Screening Recommendations / Appropriateness Criteria. <a href="https://www.acr.org/" target="_blank" rel="noopener">https://www.acr.org/</a></li>
        <li>National Cancer Institute (NCI). Breast Cancer Risk Assessment Tool (Gail Model/BCRAT). <a href="https://bcrisktool.cancer.gov/" target="_blank" rel="noopener">https://bcrisktool.cancer.gov/</a></li>
        <li>IBIS / Tyrer-Cuzick breast cancer risk evaluation (information portal). <a href="https://www.ibis-risk-calculator.com/" target="_blank" rel="noopener">https://www.ibis-risk-calculator.com/</a></li>
        <li>CanRisk / BOADICEA risk tool (hereditary risk modeling). <a href="https://www.canrisk.org/" target="_blank" rel="noopener">https://www.canrisk.org/</a></li>
        <li>Dense breast information resources (patient-focused). <a href="https://densebreast-info.org/" target="_blank" rel="noopener">https://densebreast-info.org/</a></li>
        <li>Women’s Health Initiative (WHI) publications on menopausal hormone therapy and breast cancer outcomes. <a href="https://www.whi.org/" target="_blank" rel="noopener">https://www.whi.org/</a></li>
        <li>International Breast Cancer Intervention Study (IBIS) trials and prevention data (tamoxifen/anastrozole). <a href="https://www.ctsu.ox.ac.uk/research/ibis" target="_blank" rel="noopener">https://www.ctsu.ox.ac.uk/research/ibis</a></li>
        <li>MAP.3 trial (exemestane for breast cancer prevention in postmenopausal women). <a href="https://clinicaltrials.gov/" target="_blank" rel="noopener">https://clinicaltrials.gov/</a></li>
        <li>National Comprehensive Cancer Network (NCCN) Guidelines (patient and clinician resources as applicable). <a href="https://www.nccn.org/" target="_blank" rel="noopener">https://www.nccn.org/</a></li>
        <li>National Institutes of Health (NIH) Office of Dietary Supplements (supplement safety and evidence summaries). <a href="https://ods.od.nih.gov/" target="_blank" rel="noopener">https://ods.od.nih.gov/</a></li>
      </ol>

      <footer class="amh-footer">
        <div class="amh-disclaimer medical-disclaimer">
          <p><strong>Medical disclaimer:</strong> The information on this page is provided for general educational purposes only and is not medical advice.
          It does not replace an individualized evaluation by a qualified clinician. If you have urgent symptoms, seek urgent medical care.</p>
        </div>
        <div class="amh-copyright copyright">
          <p>&copy; <span id="year"></span> Archangel Michael Health. All rights reserved.</p>
        </div>
      </footer>
    </div>
  </div>

  <script>
    (function () {
      // ---- Dynamic year ----
      var yearEl = document.getElementById("year");
      if (yearEl) yearEl.textContent = new Date().getFullYear();

      // ---- Smooth scrolling for hash links ----
      function scrollToId(id) {
        var el = document.getElementById(id);
        if (!el) return;
        el.scrollIntoView({ behavior: "smooth", block: "start" });
      }

      document.addEventListener("click", function (e) {
        var btn = e.target.closest(".toc-btn[data-scroll]");
        if (btn) {
          e.preventDefault();
          scrollToId(btn.getAttribute("data-scroll"));
          return;
        }

        var link = e.target.closest('.toc a[href^="#"]');
        if (link) {
          var hash = link.getAttribute("href");
          var target = hash && hash.length > 1 ? hash.slice(1) : null;
          if (!target) return;
          e.preventDefault();
          scrollToId(target);
          history.replaceState(null, "", hash);
        }
      });

      // ---- Download PDF using html2pdf.js ----
      var btn = document.getElementById("downloadPdfBtn");
      if (!btn) return;

      function safeFilename(title) {
        return (title || "patient-guide")
          .toLowerCase()
          .replace(/[^a-z0-9]+/g, "-")
          .replace(/(^-|-$)/g, "");
      }

      btn.addEventListener("click", function () {
        if (typeof html2pdf === "undefined") {
          alert("PDF generator is still loading. Please try again in a moment, or use Print / Save as PDF.");
          return;
        }

        btn.disabled = true;
        btn.textContent = "Preparing PDF...";

        var title = (document.getElementById("page-title") && document.getElementById("page-title").textContent) || "Patient Guide";
        var filename = safeFilename(title) + ".pdf";

        // Clone content for PDF and remove UI elements
        var source = document.getElementById("pdf-root").cloneNode(true);
        source.querySelectorAll(".no-print").forEach(function (el) { el.remove(); });

        var wrapper = document.createElement("div");
        wrapper.style.background = "#ffffff";
        wrapper.appendChild(source);

        var opt = {
          margin: [0.5, 0.5, 0.6, 0.5], // inches
          filename: filename,
          image: { type: "jpeg", quality: 0.98 },
          html2canvas: { scale: 2, useCORS: true, letterRendering: true },
          jsPDF: { unit: "in", format: "letter", orientation: "portrait" },
          pagebreak: { mode: ["css", "legacy"] }
        };

        html2pdf()
          .set(opt)
          .from(wrapper)
          .save()
          .catch(function (err) {
            console.error(err);
            alert("Could not generate the PDF in this browser. Please use Print / Save as PDF.");
          })
          .finally(function () {
            btn.disabled = false;
            btn.textContent = "Download PDF";
          });
      });
    })();
  </script>
</body>
</html>
